Meta-Flux,都柏林生物技术创办公司,筹集了1.8M欧元,以扩大其AI平台,通过整合生物数据来尽早确定治疗方法,改善临床前药物开发。 Meta-Flux, a Dublin biotech startup, raised €1.8M to expand its AI platform that improves preclinical drug development by integrating biological data to identify treatments earlier.

总部位于都柏林的生物技术初创公司Meta-Flux已筹集了180万欧元的种子资金,以扩大其以人工智能为驱动的平台,旨在提高临床前药物开发的准确性. Dublin-based biotech startup Meta-Flux has raised €1.8 million in seed funding to expand its AI-driven platform aimed at improving accuracy in preclinical drug development. 该公司由李·夏洛克和布兰登·马丁在肺癌造成个人损失后创建,该公司利用大赦国际整合遗传、蛋白质和代谢数据,模拟疾病,以确定早期开发的有前途的治疗和病人分组。 Founded by Lee Sherlock and Brendan Martin after personal losses to lung cancer, the company uses AI to integrate genetic, protein, and metabolic data, simulating diseases to identify promising treatments and patient subgroups earlier in development. 通过来自瑞,默克,吉利德科学,谷歌,亚马逊和Indeed的高管的支持,以及包括Techstars Chicago和MassBio DRIVE在内的加速器计划的支持,Meta-Flux正在扩大其团队,以加强欧盟和美国的合作. Backed by executives from Pfizer, Merck, Gilead Sciences, Google, Amazon, and Indeed, and supported by accelerator programs including Techstars Chicago and MassBio DRIVE, Meta-Flux is expanding its team to strengthen collaborations across the EU and U.S. 该公司已经在试点方案、查明新的生物标志和临床预科风险方面取得成功。 The company has already demonstrated success in pilot programs, identifying novel biomarkers and preclinical risks. 其平台建立在“生物学第一”AI模型上,旨在减少药物开发失败和成本,有可能在18个月内改变临床前研究。 Its platform, built on "biology-first" AI models, aims to reduce drug development failures and costs, with the potential to transform preclinical research within 18 months.